CN117295711A - Kv7通道开放剂的前药 - Google Patents

Kv7通道开放剂的前药 Download PDF

Info

Publication number
CN117295711A
CN117295711A CN202280034079.2A CN202280034079A CN117295711A CN 117295711 A CN117295711 A CN 117295711A CN 202280034079 A CN202280034079 A CN 202280034079A CN 117295711 A CN117295711 A CN 117295711A
Authority
CN
China
Prior art keywords
disorders
depression
disease
dystonia
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280034079.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·S·克雷安
E·G·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aikeswaizagen Co ltd
Original Assignee
Aikeswaizagen Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aikeswaizagen Co ltd filed Critical Aikeswaizagen Co ltd
Publication of CN117295711A publication Critical patent/CN117295711A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
CN202280034079.2A 2021-03-19 2022-03-20 Kv7通道开放剂的前药 Pending CN117295711A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163163470P 2021-03-19 2021-03-19
US63/163,470 2021-03-19
PCT/US2022/021057 WO2022198114A1 (en) 2021-03-19 2022-03-20 Prodrugs of kv7 channel openers

Publications (1)

Publication Number Publication Date
CN117295711A true CN117295711A (zh) 2023-12-26

Family

ID=83321210

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202280034079.2A Pending CN117295711A (zh) 2021-03-19 2022-03-20 Kv7通道开放剂的前药
CN202280034761.1A Pending CN117355503A (zh) 2021-03-19 2022-03-20 Kv7通道开放剂的前药
CN202280034756.0A Pending CN117321031A (zh) 2021-03-19 2022-03-20 Kv7通道开放剂的前药

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202280034761.1A Pending CN117355503A (zh) 2021-03-19 2022-03-20 Kv7通道开放剂的前药
CN202280034756.0A Pending CN117321031A (zh) 2021-03-19 2022-03-20 Kv7通道开放剂的前药

Country Status (11)

Country Link
US (3) US20240300894A1 (https=)
EP (3) EP4308545A4 (https=)
JP (2) JP2024511057A (https=)
KR (2) KR20230159506A (https=)
CN (3) CN117295711A (https=)
AU (3) AU2022240779A1 (https=)
BR (2) BR112023019074A2 (https=)
CA (3) CA3214270A1 (https=)
IL (2) IL306005A (https=)
MX (2) MX2023010976A (https=)
WO (3) WO2022198116A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118553447A (zh) * 2024-07-30 2024-08-27 四川大学华西医院 动态惊恐障碍治疗方案推荐系统、治疗系统及存储介质

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117860727A (zh) * 2022-09-26 2024-04-12 江苏海洋大学 一种用于预防或治疗疼痛的药物组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384330A (en) * 1992-01-08 1995-01-24 Asta Medica Aktiengesellschaft Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositions containing them
CN102159535A (zh) * 2008-07-22 2011-08-17 特拉维夫大学拉莫特有限公司 钾离子通道调节剂及其用途
CN103073455A (zh) * 2011-10-25 2013-05-01 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
WO2013179298A2 (en) * 2012-04-23 2013-12-05 Cadila Healthcare Limited A process for preparation of phenyl carbamate derivative and polymorphic forms thereof
WO2016077724A1 (en) * 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004115450A (ja) * 2002-09-27 2004-04-15 Tanabe Seiyaku Co Ltd 医薬組成物
US20060004197A1 (en) * 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
TWI453013B (zh) * 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
AU2009270768A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
MX2018015251A (es) * 2016-06-10 2019-04-25 Scifluor Life Sciences Inc Derivados de 2-amino-4-(amino sustituido)fenil carbamato fluorinado.
AU2019335070A1 (en) * 2018-09-06 2021-05-13 Ian Cooke Method of treating a sleep breathing disorder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384330A (en) * 1992-01-08 1995-01-24 Asta Medica Aktiengesellschaft Pharmaceutically active 1,2,4-triamino-benzene derivatives, processes for their preparation and pharmaceutical compositions containing them
CN102159535A (zh) * 2008-07-22 2011-08-17 特拉维夫大学拉莫特有限公司 钾离子通道调节剂及其用途
CN103073455A (zh) * 2011-10-25 2013-05-01 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
WO2013179298A2 (en) * 2012-04-23 2013-12-05 Cadila Healthcare Limited A process for preparation of phenyl carbamate derivative and polymorphic forms thereof
WO2016077724A1 (en) * 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118553447A (zh) * 2024-07-30 2024-08-27 四川大学华西医院 动态惊恐障碍治疗方案推荐系统、治疗系统及存储介质
CN118553447B (zh) * 2024-07-30 2024-11-08 四川大学华西医院 动态惊恐障碍治疗方案推荐系统、治疗系统及存储介质

Also Published As

Publication number Publication date
IL306004A (en) 2023-11-01
US20240228434A1 (en) 2024-07-11
CA3214270A1 (en) 2022-09-22
AU2022237675A1 (en) 2023-10-12
BR112023019077A2 (pt) 2023-12-05
IL306005A (en) 2023-11-01
US20240300894A1 (en) 2024-09-12
JP2024511997A (ja) 2024-03-18
BR112023019074A2 (pt) 2023-12-05
MX2023010978A (es) 2023-12-07
EP4308544A1 (en) 2024-01-24
WO2022198116A1 (en) 2022-09-22
KR20230159506A (ko) 2023-11-21
WO2022198116A9 (en) 2022-10-27
MX2023010976A (es) 2023-12-07
AU2022240779A1 (en) 2023-10-12
CA3214084A1 (en) 2022-09-22
CA3214305A1 (en) 2022-09-22
AU2022239618A1 (en) 2023-10-05
KR20230159531A (ko) 2023-11-21
CN117355503A (zh) 2024-01-05
JP2024511057A (ja) 2024-03-12
EP4308543A4 (en) 2025-04-30
EP4308544A4 (en) 2025-04-30
WO2022198115A1 (en) 2022-09-22
EP4308543A1 (en) 2024-01-24
EP4308545A1 (en) 2024-01-24
EP4308545A4 (en) 2025-04-30
CN117321031A (zh) 2023-12-29
WO2022198116A8 (en) 2023-11-09
WO2022198114A1 (en) 2022-09-22
US20240208896A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
US20250388562A1 (en) Small molecule degraders of helios and methods of use
JP6873433B2 (ja) タンパク質分解のイミド系修飾因子および関連の使用方法
AU781064B2 (en) Di-substituted iminoheterocyclic compounds
CN117295711A (zh) Kv7通道开放剂的前药
TW201536793A (zh) Ｂａｃｅ抑制劑
JP2022523702A (ja) トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
KR20250051780A (ko) (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산의합성을 위한 공정
US8765953B2 (en) Compounds and methods for the treatment of pain and other diseases
CN111954663A (zh) 氟化的4-(取代的氨基)苯基氨基甲酸酯衍生物
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
US9505743B2 (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
JP2007514658A (ja) Ｎ−アシル−ｎ’−ベンジルアルキレンジアミノ誘導体
EP4547645A1 (en) Selective histone deacetylase 3 (hdac3) degraders and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination